Mayo Medical Laboratories (MML)- Second tier testing for NBS

The Michigan Department of Health and Human Services Bureau of Laboratories is issuing a Notice of Intent to negotiate and contract with a single provider, Mayo Medical Laboratories, for second-tier newborn screening testing on dried blood spots, with written questions due October 28, 2026, at 3:00 PM EST. The state maintains that Mayo Medical Laboratories is the sole viable provider for these tests, so the procurement is sole-source in intent. Interested vendors that dispute this must submit a written response through SIGMA by November 2, 2026, at 1:59 PM EST, describing equivalent products or services.

The intended contractor is Mayo Collaborative Services, Inc., Vendor #CV0050311. The scope covers second-tier testing and interpretation of results across seven disease categories with defined analyte requirements: congenital adrenal hyperplasia; propionic acidemia, methylmalonic acidemia, and homocystinuria; mucopolysaccharidoses types I through IV; Pompe disease; maple syrup urine disease; glutaric acidemia; and X-linked adrenoleukodystrophy. The notice is classified under commodity code 94855, Medical and Laboratory Services (Non-Physician).

The contract is structured as a minimum three-year term with five optional one-year renewals. Solicitation manager Wanda Rademacher is the point of contact. All documentation and answers to questions will be posted at www.michigan.gov/SIGMAVSS, and all questions and responses must be submitted electronically through SIGMA in writing.